Controlling murine and rat chronic pain through A 3 adenosine receptor activation
- 25 January 2012
- journal article
- research article
- Published by Wiley in The FASEB Journal
- Vol. 26 (5), 1855-1865
- https://doi.org/10.1096/fj.11-201541
Abstract
Clinical management of chronic neuropathic pain is limited by marginal effectiveness and unacceptable side effects of current drugs. We demonstrate A(3) adenosine receptor (A(3)AR) agonism as a new target-based therapeutic strategy. The development of mechanoallodynia in a well-characterized mouse model of neuropathic pain following chronic constriction injury of the sciatic nerve was rapidly and dose-dependently reversed by the A(3)AR agonists: IB-MECA, its 2-chlorinated analog (Cl-IB-MECA), and the structurally distinct MRS1898. These effects were naloxone insensitive and thus are not opioid receptor mediated. IB-MECA was ≥1.6-fold more efficacious than morphine and >5-fold more potent. In addition, IB-MECA was equally efficacious as gabapentin (Neurontin) or amitriptyline, but respectively >350- and >75-fold more potent. Besides its potent standalone ability to reverse established mechanoallodynia, IB-MECA significantly increased the antiallodynic effects of all 3 analgesics. Moreover, neuropathic pain development in rats caused by widely used chemotherapeutics in the taxane (paclitaxel), platinum-complex (oxaliplatin), and proteasome-inhibitor (bortezomib) classes was blocked by IB-MECA without antagonizing their antitumor effect. A(3)AR agonist effects were blocked with A(3)AR antagonist MRS1523, but not with A(1)AR (DPCPX) or A(2A)AR (SCH-442416) antagonists. Our findings provide the scientific rationale and pharmacological basis for therapeutic development of A(3)AR agonists for chronic pain.Keywords
Funding Information
- National Institutes of Health (R01 DA024074)
This publication has 58 references indexed in Scilit:
- Functional deficits in peripheral nerve mitochondria in rats with paclitaxel- and oxaliplatin-evoked painful peripheral neuropathyExperimental Neurology, 2011
- Pharmacological and therapeutic effects of A3 adenosine receptor agonistsDrug Discovery Today, 2011
- Allosteric Modulation of Purine and Pyrimidine ReceptorsPublished by Elsevier BV ,2011
- International Union of Basic and Clinical Pharmacology. LXXXI. Nomenclature and Classification of Adenosine Receptors—An UpdatePharmacological Reviews, 2011
- Pain-relieving prospects for adenosine receptors and ectonucleotidasesTrends in Molecular Medicine, 2011
- CF102 an A3 adenosine receptor agonist mediates anti‐tumor and anti‐inflammatory effects in the liverJournal of Cellular Physiology, 2010
- The A3 adenosine receptor attenuates the calcium rise triggered by NMDA receptors in retinal ganglion cellsNeurochemistry International, 2010
- Modulation of cellular redox state underlies antagonism between oxaliplatin and cetuximab in human colorectal cancer cell linesBritish Journal of Pharmacology, 2009
- Synthesis and pharmacological characterization of [125I]MRS1898, a high-affinity, selective radioligand for the rat A3 adenosine receptorPurinergic Signalling, 2008
- Cl-IB-MECA [2-Chloro-N6-(3-iodobenzyl)adenosine-5′-N-methylcarboxamide] Reduces Ischemia/Reperfusion Injury in Mice by Activating the A Adenosine ReceptorJournal of Pharmacology and Experimental Therapeutics, 2006